Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 25587 | 230 | 39.9 | 90% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | M65 | Author keyword | 26 | 80% | 7% | 16 |
| 2 | M30 | Author keyword | 11 | 37% | 11% | 25 |
| 3 | M65 ELISA | Author keyword | 6 | 100% | 2% | 4 |
| 4 | SERUM M30 LEVEL | Author keyword | 6 | 100% | 2% | 4 |
| 5 | SERUM M65 LEVEL | Author keyword | 6 | 100% | 2% | 4 |
| 6 | CYTOKERATIN 18 | Author keyword | 5 | 19% | 11% | 26 |
| 7 | CLIN EXPT PHARMACOL CEP GRP | Address | 4 | 75% | 1% | 3 |
| 8 | M30 ELISA | Author keyword | 3 | 100% | 1% | 3 |
| 9 | CK18 | Author keyword | 3 | 42% | 2% | 5 |
| 10 | CELL DEATH BIOMARKERS | Author keyword | 2 | 67% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | M65 | 26 | 80% | 7% | 16 | Search M65 | Search M65 |
| 2 | M30 | 11 | 37% | 11% | 25 | Search M30 | Search M30 |
| 3 | M65 ELISA | 6 | 100% | 2% | 4 | Search M65+ELISA | Search M65+ELISA |
| 4 | SERUM M30 LEVEL | 6 | 100% | 2% | 4 | Search SERUM+M30+LEVEL | Search SERUM+M30+LEVEL |
| 5 | SERUM M65 LEVEL | 6 | 100% | 2% | 4 | Search SERUM+M65+LEVEL | Search SERUM+M65+LEVEL |
| 6 | CYTOKERATIN 18 | 5 | 19% | 11% | 26 | Search CYTOKERATIN+18 | Search CYTOKERATIN+18 |
| 7 | M30 ELISA | 3 | 100% | 1% | 3 | Search M30+ELISA | Search M30+ELISA |
| 8 | CK18 | 3 | 42% | 2% | 5 | Search CK18 | Search CK18 |
| 9 | CELL DEATH BIOMARKERS | 2 | 67% | 1% | 2 | Search CELL+DEATH+BIOMARKERS | Search CELL+DEATH+BIOMARKERS |
| 10 | SIGNIFICANT INFLAMMATION | 2 | 67% | 1% | 2 | Search SIGNIFICANT+INFLAMMATION | Search SIGNIFICANT+INFLAMMATION |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CASPASE CLEAVED CYTOKERATIN 18 | 38 | 78% | 11% | 25 |
| 2 | CYTOKERATIN 18 | 8 | 28% | 11% | 25 |
| 3 | CIRCULATING BIOMARKERS | 8 | 46% | 6% | 13 |
| 4 | M30 | 8 | 50% | 5% | 11 |
| 5 | M65 ELISAS | 6 | 80% | 2% | 4 |
| 6 | PRO APOPTOTIC DRUGS | 5 | 63% | 2% | 5 |
| 7 | EXTRACELLULAR CYTOKERATIN 18 | 4 | 50% | 3% | 6 |
| 8 | APOPTOSIS PROTEIN XIAP | 3 | 17% | 6% | 14 |
| 9 | LIVER CELL APOPTOSIS | 1 | 50% | 1% | 2 |
| 10 | DUCT LIGATED MOUSE | 1 | 24% | 2% | 5 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Systematic review: caspase-cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease | 2009 | 30 | 30 | 43% |
| Utilization of cytokeratin-based biomarkers for pharmacodynamic studies | 2010 | 15 | 46 | 46% |
| Apoptosis as a Mechanism for Liver Disease Progression | 2010 | 54 | 90 | 12% |
| A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery | 2014 | 4 | 11 | 18% |
| Biomarkers of cell death applicable to early clinical trials | 2012 | 7 | 56 | 20% |
| Biomarker method validation in anticancer drug development | 2008 | 53 | 78 | 22% |
| Utility of M30, an apoptotic serum marker, in liver diseases | 2015 | 0 | 36 | 42% |
| Cellular and molecular mechanisms of liver injury | 2008 | 191 | 114 | 8% |
| Biomarkers of apoptosis | 2008 | 29 | 26 | 27% |
| Biomarkers for Hepatocellular Apoptosis in the Management of Liver Diseases | 2012 | 2 | 66 | 29% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CLIN EXPT PHARMACOL CEP GRP | 4 | 75% | 1.3% | 3 |
| 2 | CLIN EXPT PHARMACOL GRP | 2 | 18% | 4.8% | 11 |
| 3 | MEDIZIN KLIN 1 | 1 | 50% | 0.4% | 1 |
| 4 | OPTOSIS BIOMARKERS | 1 | 50% | 0.4% | 1 |
| 5 | OWEN ELLEN EVANS CHAIR CANC STUDIES | 1 | 50% | 0.4% | 1 |
| 6 | TRANSLAT ANGIOGENESIS GRP | 1 | 25% | 0.9% | 2 |
| 7 | CANC THER EUTHADDOW S | 0 | 33% | 0.4% | 1 |
| 8 | KAROLINSKA EXPT IMAGING | 0 | 33% | 0.4% | 1 |
| 9 | MANISA HLTH SCI | 0 | 33% | 0.4% | 1 |
| 10 | PET RADIOCHEM | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000116337 | LEUCINE RICH ALPHA 2 GLYCOPROTEIN 1//GLOBAL OLARS PROGRAM//LRG1 |
| 2 | 0.0000109174 | PACHYONYCHIA CONGENITA//EPIDERMOLYSIS BULLOSA SIMPLEX//EPIDERMOLYTIC HYPERKERATOSIS |
| 3 | 0.0000085211 | CYFRA 21 1//CYTOKERATIN 19 FRAGMENTS//PROGRP |
| 4 | 0.0000084367 | CA 15 3//CA 153//TISSUE POLYPEPTIDE SPECIFIC ANTIGEN |
| 5 | 0.0000083649 | FAS//FAS LIGAND//AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME |
| 6 | 0.0000075228 | D GALACTOSAMINE//BICYCLOL//CON A INDUCED HEPATITIS |
| 7 | 0.0000067565 | CIRCULATING DNA//CELL FREE DNA//CIRCULATING CELL FREE DNA |
| 8 | 0.0000064762 | URSODEOXYCHOLIC ACID//TAUROURSODEOXYCHOLIC ACID//TAUROURSODEOXYCHOLATE |
| 9 | 0.0000062397 | APAF 1//CASPASE 2//RAIDD |
| 10 | 0.0000052763 | NON ALCOHOLIC FATTY LIVER DISEASE//NON ALCOHOLIC STEATOHEPATITIS//NASH |